Litigation Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

Docket		Date Filed	2017-04-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,967,208; 9,326,945
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-04-05	12		IV) for U.S. Patent Nos. 6,967,208 (“the ’208 patent”) and 9,326,945 (“the ’945 patent”). Aurobindo … (Noninfringement of U.S. Patent No. 6,967,208)   Plaintiffs will not and cannot…Invalidity of U.S. Patent No. 6,967,208)   Upon… purports to bring an action for patent infringement under the Patent Laws, 35 U.S.C. § 100 et seq… PATENTS-IN-SUIT   9. Aurobindo admits that the ’208 patent is entitled “	External link to document
2017-04-05	144		Invalidity Contentions Relating to U.S. Patent No. 6,967,208 filed by Mylan Pharmaceuticals Inc..(Stamoulis… 5 April 2017 1:17-cv-00374-LPS Patent None District Court, D. Delaware	External link to document
2017-04-05	145		Invalidity Contentions Relating to U.S. Patent No. 9,326,945 filed by Mylan Pharmaceuticals Inc..(Stamoulis… 5 April 2017 1:17-cv-00374-LPS Patent None District Court, D. Delaware	External link to document
2017-04-05	380		of U.S. Patent Nos. 9,326,945 ("'945 patent") and 6,967,208 ('"208 patent")…arts, such as the salts disclosed at U.S . Patent No. 6,967,208, column 116, lines 51-67, and in Remington…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification … TERMS A. '208 Patent The '208 patent is entitled "Lactam-containing	External link to document
2017-04-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,967,208 B2; US 9,326,945 … 5 April 2017 1:17-cv-00374-LPS Patent None District Court, D. Delaware	External link to document

Bristol-Myers Squibb v. Aurobindo Pharma: Eliquis Patent Litigation Summary and Analysis, 1:17-cv-00374-LPS

Last updated: August 23, 2026

Bristol-Myers Squibb Company sued Aurobindo Pharma USA Inc. in the U.S. District Court for the District of Delaware after Aurobindo filed an abbreviated new drug application seeking approval for generic apixaban tablets, the active ingredient in Eliquis. The case was a Hatch-Waxman Paragraph IV patent action involving Eliquis patents listed in the FDA Orange Book. The litigation ended without a publicly reported merits judgment. The parties resolved the dispute and the case was dismissed pursuant to a stipulation, leaving the commercial terms and any agreed generic launch date outside the public docket.

What was Bristol-Myers Squibb v. Aurobindo about?

The case concerned Aurobindo’s proposed generic versions of Eliquis, an oral direct factor Xa inhibitor used to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation and to treat or prevent venous thromboembolism.

Bristol-Myers Squibb alleged that Aurobindo’s ANDA product would infringe Eliquis patents under 35 U.S.C. § 271(e)(2). The case was filed on February 17, 2017, in the District of Delaware and assigned to Judge Leonard P. Stark under civil action number 1:17-cv-00374-LPS. [1]

Key case data

Field	Details
Plaintiffs	Bristol-Myers Squibb Company
Defendant	Aurobindo Pharma USA Inc.
Court	U.S. District Court for the District of Delaware
Civil action	1:17-cv-00374-LPS
Judge	Leonard P. Stark
Filing date	February 17, 2017
Product	Generic apixaban tablets
Reference drug	Eliquis
Dosage strengths	2.5 mg and 5 mg tablets
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Triggering event	Aurobindo Paragraph IV ANDA certification
Public disposition	Dismissed pursuant to settlement-related stipulation
Merits judgment	None publicly reported

What patents protected Eliquis in the Aurobindo litigation?

The action involved Bristol-Myers Squibb’s Eliquis patent estate, including U.S. Patent No. 6,967,208 and U.S. Patent No. 9,326,945. These patents were listed in the FDA Orange Book for apixaban products and formed part of the patent barrier asserted against generic applicants. [1][2]

U.S. Patent No. 6,967,208

The ’208 patent covers apixaban-related chemical subject matter and is generally treated as the principal composition-of-matter patent for Eliquis. The patent was assigned to Bristol-Myers Squibb Company and has an expiration date in December 2026, subject to the applicable pediatric extension. [2][3]

The patent’s commercial importance derives from the breadth and timing of composition-of-matter protection. A successful challenge to the ’208 patent could have materially reduced the remaining exclusivity period for Eliquis, although other listed patents and regulatory exclusivities could still affect launch timing.

U.S. Patent No. 9,326,945

The ’945 patent covers additional apixaban-related pharmaceutical subject matter, including compositions and related use limitations identified in the patent and Orange Book records. The patent is associated with the later portion of the Eliquis patent estate and has an expiration date tied to the underlying patent term framework. [2][4]

The ’945 patent was important because it provided a second infringement and validity dispute after Aurobindo’s ANDA filing. In Hatch-Waxman litigation, multiple Orange Book patents increase the number of claims a generic applicant must overcome before obtaining an unrestrained launch.

Patent protection timeline

Patent	General subject matter	Orange Book role	Listed expiration framework
U.S. 6,967,208	Apixaban chemical/composition claims	Core Eliquis patent	December 2026, with pediatric extension potentially extending protection into June 2027
U.S. 9,326,945	Apixaban pharmaceutical composition and related claims	Additional listed patent	Term tied to the Eliquis patent estate and applicable terminal-disclaimer or patent-term rules

The precise enforceability of each patent depends on claim scope, prosecution history, terminal disclaimers, patent-term adjustment, and any pediatric exclusivity. The public Aurobindo docket did not produce a final claim-construction or validity decision resolving those issues.

How did Aurobindo’s Paragraph IV certification affect the case?

Aurobindo’s Paragraph IV certification asserted that the relevant Eliquis patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Under the Hatch-Waxman Act, submitting an ANDA with a Paragraph IV certification can constitute an artificial act of infringement under 35 U.S.C. § 271(e)(2). [5]

Bristol-Myers Squibb’s lawsuit activated the statutory framework that can delay FDA approval of the ANDA. The filing of a timely patent action generally creates a 30-month stay of final FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the court orders otherwise or the dispute is resolved earlier. [5]

Practical consequences of the Paragraph IV filing

Aurobindo’s certification created several immediate effects:

1. Bristol-Myers Squibb obtained a statutory basis to sue before commercial launch.
2. FDA approval could be delayed during the statutory stay.
3. Aurobindo gained potential first-filer rights if it was eligible for 180-day generic exclusivity.
4. The parties obtained leverage to negotiate an early-entry settlement.
5. The litigation shifted the commercial launch question from FDA approval alone to patent clearance and settlement terms.

The public case record does not establish that Aurobindo obtained a final judgment of invalidity or noninfringement. It also does not disclose the precise terms of any agreed launch license.

When did the Aurobindo Eliquis litigation end?

The case ended through a settlement-related dismissal rather than a public trial judgment. The court docket reflects a stipulation dismissing the action. The settlement terms were not filed in a form that publicly establishes the agreed launch date, royalty structure, authorized-generic provisions, or restrictions on future challenges. [1]

What the dismissal means

The dismissal has four principal implications:

• Aurobindo did not receive a public merits ruling invalidating the asserted Eliquis patents.
• Bristol-Myers Squibb did not receive a public merits ruling confirming infringement and validity.
• The immediate dispute over Aurobindo’s ANDA was resolved contractually.
• The commercial outcome depended on confidential settlement provisions rather than the docket alone.

A dismissal following settlement does not establish that the asserted patents were strong or weak on the merits. It shows that the parties allocated litigation and launch risk through agreement.

Did Bristol-Myers Squibb win the case against Aurobindo?

No public merits judgment establishes a conventional winner. Bristol-Myers Squibb achieved dismissal of the infringement action without an adverse judgment, while Aurobindo avoided a trial judgment that could have blocked its ANDA or exposed it to an adverse finding on infringement.

From a commercial perspective, Bristol-Myers Squibb retained control over the timing and conditions of Aurobindo’s potential entry through the settlement. Aurobindo obtained a negotiated resolution and avoided the cost and uncertainty of a full Delaware patent trial. The economic value of that tradeoff cannot be measured from the public docket because the settlement terms are confidential.

How strong was Bristol-Myers Squibb’s Eliquis patent estate?

The Eliquis estate was commercially strong but legally untested in this particular action.

Factors supporting patent strength

The estate had several characteristics favorable to the brand company:

• A listed composition-of-matter patent with protection extending beyond the initial FDA approval period.
• Multiple Orange Book patents rather than a single asserted patent.
• A high-value product with substantial revenue exposure.
• The ability to invoke the Hatch-Waxman 30-month stay.
• The ability to negotiate with multiple ANDA applicants independently.
• A regulatory product with no biosimilar pathway available to competitors.

Factors limiting the analysis

The public record does not provide a final determination on:

• Claim construction.
• Anticipation.
• Obviousness.
• Written description.
• Enablement.
• Enforceability.
• Infringement by Aurobindo’s specific formulation.
• The effect of any prosecution-history estoppel.

The absence of a merits opinion is important. Patent listings and settlement outcomes demonstrate exclusionary leverage, but they do not conclusively validate the claims.

What formulation and method-of-use patents affected generic apixaban?

Eliquis protection involved more than the active pharmaceutical ingredient. Orange Book-listed and related patents can cover pharmaceutical compositions, tablet formulations, dosage regimens, and approved methods of use.

Formulation protection

Formulation claims can be relevant when a generic applicant proposes the same active ingredient and dosage strengths but must demonstrate bioequivalence using a particular tablet composition or manufacturing process. A generic may attempt to design around formulation claims while preserving bioequivalence.

The ’945 patent formed part of this additional protection layer. Its presence increased the number of legal theories Bristol-Myers Squibb could assert against Aurobindo, although the public record does not show a final ruling on the scope or validity of the asserted claims.

Method-of-use protection

Method-of-use patents may cover the administration of apixaban for indications such as prevention of stroke in nonvalvular atrial fibrillation or treatment and prevention of venous thromboembolism. A generic applicant can sometimes use a “skinny label” that omits patented indications under the Hatch-Waxman framework.

That strategy does not automatically eliminate infringement risk. Liability may still depend on the proposed label, promotional conduct, physician and pharmacy behavior, and whether the generic product is directed toward the patented use. The Aurobindo docket does not supply a public merits analysis resolving those issues.

What was the FDA and Orange Book status of Eliquis?

Eliquis is an FDA-approved small-molecule drug, not a biologic. Aurobindo therefore proceeded through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

Regulatory status

Regulatory issue	Analysis
Reference product	Eliquis, apixaban
FDA pathway for generic	ANDA under 21 U.S.C. § 355(j)
Certification	Paragraph IV
Patent listing	Eliquis patents listed in the Orange Book
Biosimilar risk	Not applicable because apixaban is a small molecule
Approval barrier	Patent stay, patent settlement, or final court resolution
Commercial risk	Launch timing dependent on patent clearance and settlement terms

The Orange Book listing gave Bristol-Myers Squibb a statutory platform to enforce the patents against ANDA applicants. It did not, by itself, establish that the patents would survive invalidity challenges.

Which companies challenged the Eliquis patent estate?

Aurobindo was one of several generic manufacturers that filed ANDAs or otherwise became involved in Eliquis patent disputes. Publicly reported Eliquis litigation included actions involving companies such as Teva, Mylan, Amneal, Sigmapharm, Micro Labs, and other generic applicants. [6]

The multi-defendant litigation strategy mattered commercially. Bristol-Myers Squibb could negotiate separately with each applicant, but a settlement with one generic could affect the bargaining position of others. The first applicant to file an eligible Paragraph IV certification could also have a potential 180-day exclusivity position, subject to forfeiture and other statutory rules.

What generic entry risks existed after the Aurobindo settlement?

The settlement eliminated the immediate risk of an Aurobindo launch during the active litigation but did not eliminate long-term generic erosion risk.

Near-term risk

The case dismissal removed the need for a trial in the Aurobindo action. Unless the settlement permitted an earlier launch, Aurobindo’s ability to market generic apixaban remained contractually constrained.

Post-expiration risk

The larger risk arose from the expiration of the core Eliquis patents and any agreed launch dates with multiple generic applicants. Once several manufacturers enter, price competition can be rapid because:

• Apixaban is a tablet dosage form.
• Manufacturing complexity is lower than for biologics.
• Multiple ANDA applicants can compete simultaneously.
• Pharmacy substitution can accelerate volume migration.
• Payers can use formulary pressure to favor lower-cost alternatives.

Authorized generic risk

An authorized generic launched by or for the brand company could reduce the price advantage available to independent generic entrants while allowing Bristol-Myers Squibb or its commercial partners to retain part of the generic market economics. The public Aurobindo docket does not disclose whether the settlement included an authorized-generic commitment.

What revenue exposure did the litigation create?

Eliquis was a major revenue product for both Bristol-Myers Squibb and Pfizer. Combined global Eliquis revenue was approximately $12.6 billion in 2023, based on reported company results. [7][8]

The relevant exposure was larger than the revenue attributable to Aurobindo alone. A negotiated Aurobindo launch could have affected:

• Bristol-Myers Squibb’s and Pfizer’s U.S. sales.
• Net pricing before and after generic entry.
• Rebate and contracting strategy.
• The timing of formulary substitution.
• The value of remaining patent settlements.
• Forecasts for the product’s post-exclusivity decline.

A single generic entrant often has limited impact before broad market entry. The larger commercial inflection point occurs when several ANDA applicants launch near the same date or when the first entrant establishes a lower market price.

How does this case compare with other Eliquis patent cases?

The Aurobindo action was part of a broader wave of Eliquis Paragraph IV litigation. Its procedural posture was similar to the other cases: Bristol-Myers Squibb asserted Orange Book patents after generic applicants challenged them through ANDA certifications.

Issue	Aurobindo case	Broader Eliquis litigation
Product	Apixaban tablets	Apixaban tablets
Legal framework	Hatch-Waxman	Hatch-Waxman
Patent strategy	Composition and additional Eliquis patents	Multiple Orange Book patents across defendants
Public merits decision	None reported in this action	Outcomes varied by defendant and settlement
Commercial result	Settlement-related dismissal	Staggered settlements and negotiated entry risks
Biosimilar issue	None	None

The principal analytical distinction is between a negotiated dismissal and a litigated invalidity decision. A settlement can preserve the brand company’s patent leverage while granting the generic a future commercial path. It does not answer whether the patents would have survived trial.

What licensing and settlement terms are public?

The public docket does not disclose the material economic terms of the Bristol-Myers Squibb-Aurobindo settlement. There is no publicly established launch date, royalty rate, supply arrangement, authorized-generic provision, or admission concerning patent validity.

For business planning, the case should therefore be classified as a confidential patent settlement with unresolved public commercial terms. Analysts should not treat the dismissal date as the generic launch date or assume that Aurobindo received an unrestricted right to market apixaban immediately after dismissal.

Key Takeaways

• Bristol-Myers Squibb sued Aurobindo over a Paragraph IV ANDA for generic apixaban, the active ingredient in Eliquis.
• The case was filed in the District of Delaware on February 17, 2017, as 1:17-cv-00374-LPS.
• The asserted Eliquis patent estate included U.S. Patent Nos. 6,967,208 and 9,326,945.
• The core Eliquis patent protection extended into December 2026, with pediatric exclusivity potentially extending into June 2027.
• The action ended through a settlement-related dismissal rather than a public merits judgment.
• The public docket does not disclose Aurobindo’s agreed launch date or other settlement economics.
• The case involved a small-molecule ANDA, so biosimilar law was not relevant.
• The commercial risk was substantial because Eliquis generated approximately $12.6 billion in combined global revenue in 2023.
• The settlement preserved Bristol-Myers Squibb’s patent leverage but left the ultimate generic-entry timing dependent on confidential contractual terms and the broader Eliquis litigation landscape.

Frequently Asked Questions

What drug was involved in Bristol-Myers Squibb v. Aurobindo?

The case involved generic apixaban tablets, the active pharmaceutical ingredient in Eliquis. The proposed product included 2.5 mg and 5 mg strengths.

Was Aurobindo’s generic Eliquis approved by the FDA?

The public litigation docket does not establish the final FDA approval status or the commercial launch date associated with Aurobindo’s ANDA. The lawsuit itself concerned the patent consequences of Aurobindo’s Paragraph IV certification.

Did the Aurobindo case invalidate the Eliquis patents?

No. The case ended without a public merits judgment invalidating or upholding the asserted Eliquis patents.

Does the case create biosimilar risk for Eliquis?

No. Eliquis is a small-molecule drug regulated through the ANDA pathway. Its competitive threat comes from generic apixaban applicants, not biosimilar applicants.

What is the expected effect of generic apixaban on Eliquis sales?

Multiple generic launches can produce substantial price and volume pressure through pharmacy substitution, payer formulary changes, and competitive discounting. The size and timing of the decline depend on the number of entrants, settlement launch dates, authorized-generic strategy, and market share retained by Eliquis.

References

1. U.S. District Court for the District of Delaware. (2017). Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc., No. 1:17-cv-00374-LPS. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,967,208: Processes for preparing apixaban. U.S. Department of Commerce.

4. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,326,945: Pharmaceutical compositions comprising apixaban. U.S. Department of Commerce.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j); Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).

6. Bristol-Myers Squibb Company. (2017). Complaints concerning abbreviated new drug applications for apixaban filed against generic manufacturers. U.S. District Court for the District of Delaware.

7. Bristol-Myers Squibb Company. (2024). 2023 annual report. Bristol-Myers Squibb.

8. Pfizer Inc. (2024). 2023 annual report. Pfizer.